ASTEX PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2011-01-01
- Employees
- 136
- Market Cap
- -
- Website
- http://www.astx.com
A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)
- Conditions
- Interventions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT05835011
- Locations
- 🇺🇸
BRCR Medical Center, Plantation, Florida, United States
🇺🇸Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Yale University, New Haven, Connecticut, United States
Thorough QT Assessment of Cedazuridine in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04953923
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
- Conditions
- Interventions
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04637009
- Locations
- 🇺🇸
University of Southern California Keck School of Medicine, Los Angeles, California, United States
🇺🇸Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
🇺🇸Augusta University - Georgia Cancer Center, Augusta, Georgia, United States
Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT04479800
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04466514
- Locations
- 🇺🇸
Frontage Clinical Services, Secaucus, New Jersey, United States
A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam
- Conditions
- Interventions
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04411030
- Locations
- 🇺🇸
QPS Bio-kinetic, Springfield, Missouri, United States
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT04155580
- Locations
- 🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Franciscan Health Indianapolis (Blood and Marrow Transplantation), Indianapolis, Indiana, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Effect of Food on Blood Levels of ASTX727
- Conditions
- Interventions
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT03813186
- Locations
- 🇺🇸
Roswell Park, Buffalo, New York, United States
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸Vanderbilt, Nashville, Tennessee, United States
Guadecitabine Extension Study
- Conditions
- Interventions
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT03603964
- Locations
- 🇺🇸
Center for Blood Cancers, Nashville, Tennessee, United States
🇮🇹Azienda Ospedaliera Universitaria San Martino, Genova, Italy
🇺🇸Ohio State University, Columbus, Ohio, United States
Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML
- Conditions
- Interventions
- First Posted Date
- 2017-10-11
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 227
- Registration Number
- NCT03306264
- Locations
- 🇺🇸
West Penn Allegheny Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸University of Pittsburgh Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States